PRAX Praxis Precision Medicines, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1689548 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY365.0%
TTM net income YoY-80.8%
TTM EPS YoY-41.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,927.5%
Net margin-3,658.5%
FCF margin-3,067.4%
EBITDA margin-3,925.4%
Returns
ROE-75.2%
ROA-67.2%
ROIC (approx.)-113.5%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio5.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $8.55M | $2.45M | $0 | — |
| R&D expense | $267.12M | $152.41M | $86.77M | $155.04M | $120.26M |
| SG&A expense | $59.08M | $56.30M | $42.05M | $59.95M | $47.08M |
| Operating income | -$326.20M | -$200.16M | -$126.37M | -$214.99M | -$167.33M |
| Pretax income | -$302.80M | -$182.74M | -$123.01M | — | -$167.06M |
| Income tax | $471,000 | — | — | — | $0 |
| Net income | -$303.27M | -$182.82M | -$123.28M | -$214.03M | -$167.06M |
| EBITDA | -$326.06M | -$199.81M | -$125.94M | -$214.57M | -$167.15M |
| EPS (basic) | -13.48 | -10.21 | -18.69 | -69.65 | -3.94 |
| EPS (diluted) | -13.48 | -10.21 | -18.69 | -69.65 | -3.94 |
| Weighted avg. shares (diluted) | 22.50M | 17.91M | 6.59M | 3.07M | 42.45M |
| Balance sheet | |||||
| Cash & equivalents | $357.33M | $215.79M | $81.30M | $62.03M | $139.72M |
| Short-term investments | $242.00M | $177.19M | $0 | $38.87M | $105.68M |
| Current assets | $610.91M | $404.37M | $84.88M | $110.84M | $287.41M |
| PP&E, net | $147,000 | $230,000 | $588,000 | $971,000 | $1.21M |
| Intangibles | $0 | — | — | — | — |
| Total assets | $937.91M | $483.11M | $87.95M | $115.13M | $292.75M |
| Current liabilities | $59.77M | $37.55M | $15.75M | $34.34M | $38.43M |
| Total liabilities | $59.77M | $37.66M | $18.28M | $39.02M | $41.94M |
| Shareholders' equity | $878.14M | $445.45M | $69.67M | $76.11M | $250.81M |
| Shares outstanding | 25.20M | 19.42M | 8.79M | 3.29M | 45.30M |
| Cash flow statement | |||||
| Operating cash flow | -$249.07M | -$131.76M | -$111.14M | -$185.04M | -$124.55M |
| Capital expenditure | $56,000 | $0 | $50,000 | $444,000 | $1.05M |
| Free cash flow | -$249.12M | -$131.76M | -$111.19M | -$185.49M | -$125.60M |
| Investing cash flow | -$311.15M | -$248.49M | $38.95M | $96.89M | -$140.52M |
| Financing cash flow | $702.17M | $514.32M | $91.87M | $10.46M | $107.59M |
| Depreciation & amortization | $140,000 | $358,000 | $432,000 | $419,000 | $182,000 |
| Stock-based compensation | $33.94M | $41.36M | $24.86M | $28.59M | $22.69M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.